A frontrunner in cutting edge ophthalmology therapy
We are focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society. Our proprietary drug discovery programme is also targeting the development of antibiotic compounds as well as other systemic ophthalmology treatments.
We are also expanding our genomic drug discovery, a field at the forefront of modern life science. Through information exchange and joint study efforts with renowned genomic drug discovery external research institutes, we are committed to discovering new breakthroughs in the treatment of eye disorders.
Primary R&D domains
|Corneal and conjunctival disorders||Corneal and conjunctival epithelial disorders
Persistent corneal epithelial defects
Dry eye disease
|Glaucoma and ocular hypertension||Glaucoma|
|Retinal/uveal disorders||Diabetic macular oedema
|Ocular infections/allergies||Bacterial conjunctivitis
|Santen S.A.S. product development||Spring catarrh/severe dry eye disease
Diabetic macular oedema